A Phase I Study of Immunotherapy with IPH2201 plus Durvalumab in Patients with Metastatic Solid Tumors

Full Title

A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors

Purpose

IPH2201 and durvalumab are immunotherapy drugs. They each block proteins that may allow tumor cells to escape detection by the immune system. By blocking these two proteins, this drug combination may boost the power of the immune system to recognize and kill cancer cells, causing tumors to shrink.

In this study, researchers are finding the best dose of IPH2201 to give with durvalumab in patients with metastatic solid tumors, including non-small cell lung cancer, endometrial cancer, ovarian cancer, cervical cancer, pancreatic cancer, prostate cancer, or colorectal cancer. Both medications are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic non-small cell lung cancer, endometrial cancer, ovarian cancer, cervical cancer, pancreatic cancer, prostate cancer, or colorectal cancer that has continued to grow or came back despite prior therapy.
  • Patients may not have received prior immunotherapy.
  • Patients must recover from the serious side effects of prior treatments before entering the study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Matthew Hellmann at 646-888-4863.

Protocol

16-490

Phase

I

Investigator

Co-Investigators

Locations